PREMIUM Registry: PRognostic HEModynamIc Profiling in the AcUtely Ill EMergency Department Patient

NCT ID: NCT01208077

Last Updated: 2015-08-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

514 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-09-30

Study Completion Date

2012-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This multinational registry (3 USA, 2 European centers) will capture in the ED continuous non invasive hemodynamic monitoring (using Nexfin finger cuff technology) of patients presenting with acute heart failure, stroke syndromes and systemic infection. Patients will be observed after their Emergency Department (ED) disposition to determine clinical outcomes (length of stay in the hospital, the development of any organ dysfunction, mortality and need for unscheduled medical care within the ensuing 30 days). It is anticipated that specific ED hemodynamic profiles will be predictive of better clinical outcomes than others. This information will provide the outcome data needed to design future therapeutic trials that will evaluate the effect of ED hemodynamic manipulations on overall patient management and outcomes.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The PREMIUM Registry is a multinational, prospective, observational convenience study of the ED hemodynamic profiles of patients presenting with acute CHF, stroke and systemic infections and their potential relationship with patient outcomes. Continuous hemodynamics will be measured by noninvasive means using the Nexfin device and outcomes (in hospital length of stay, the interval development of organ dysfunction and mortality or the need for unscheduled medical care within the ensuing 30 days) will be captured within the registry.

The treating ED physicians will be blinded to the hemodynamic monitoring and there will be no modification of the standard care that each patient receives. Hospital charts will be reviewed and patients/family members will be additionally called at 30 days after the hospital visit in order to collect any additional outcome data.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute CHF Acute Stroke Syndromes Systemic Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Acute CHF

1. Recurrent or worsening (within 3 days) shortness of breath as the primary presenting ED complaint
2. Initial treating ED physician impression that the worsening dyspnea is most likely caused by decompensated CHF
3. Known history of physician diagnosed CHF
4. Natriuretic peptide (BNP, MR-pro ANP, NT pro BNP) level will be ordered by the treating physician as part of the patient's work up

No interventions assigned to this group

Acute Stroke Syndrome

1. Onset of abnormal neurological symptoms consistent with possible stroke, within the prior 24 hours, as the primary ED complaint
2. Initial treating ED physician impression that the abnormal neurological symptoms/signs are most likely caused by an acute stroke syndrome
3. Non contrast head CT will be ordered by the treating physician as part of the patient's work up

No interventions assigned to this group

Acute Systemic Infection

1. Any combinations of acute (within 3 days) symptoms and signs that the treating ED physician, after initial history and physical examination, attributes to a systemic infection
2. Blood cultures and/or a blood lactate will be ordered by the treating physician as part of the patient's work up

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 years of age or older
* Able to provide informed consent
* No initiated therapy since arrival to the ED
* Must be enrolled within 4 hours of arrival to the ED


* Recurrent or worsening (within 3 days) shortness of breath as the primary presenting ED complaint
* Initial treating ED physician impression that the worsening dyspnea is most likely caused by decompensated CHF
* Known history of physician diagnosed CHF
* Natriuretic peptide (BNP, MR-pro ANP, NT pro BNP) level will be ordered by the treating physician as part of the patient's work up


* Onset of abnormal neurological symptoms consistent with possible stroke, within the prior 24 hours, as the primary ED complaint
* Initial treating ED physician impression that the abnormal neurological symptoms/signs are most likely caused by an acute stroke syndrome
* Non contrast head CT will be ordered by the treating physician as part of the patient's work up


* Any combinations of acute (within 3 days) symptoms and signs that the treating ED physician, after initial history and physical examination, attributes to a systemic infection
* Blood cultures and/or a blood lactate will be ordered by the treating physician as part of the patient's work up

Exclusion Criteria

* ESRD requiring hemo or peritoneal dialysis
* Suspected pregnancy
* Not able to be followed up in 30 days
* Patients with "comfort only" DNR status
* Patients with known STEMI
* Excessive agitation
* Transferred from another treating facility
* Known aortic valve disease
* On continuous IV home infusions (such as milrinone, primacor)
* Known Left Ventricular Assist device (LVAD)
* Known prior enrollment in this study
* In current therapeutic Investigational study
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

BMEYE BV the Netherlands

UNKNOWN

Sponsor Role collaborator

Edwards Lifesciences

INDUSTRY

Sponsor Role collaborator

Henry Ford Health System

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Richard M Nowak

Sr, Staff Emergency Medicine

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Richard M Nowak, MD

Role: PRINCIPAL_INVESTIGATOR

Henry Ford Health System

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Detroit Receiving Hospital/Wayne State University

Detroit, Michigan, United States

Site Status

Henry Ford Hospital

Detroit, Michigan, United States

Site Status

University LaSapienza Rome Sant'Andrea Hospital

Rome, Rome, Italy

Site Status

VU University Medical Centre

Amsterdam, Amsterdam, Netherlands

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Italy Netherlands

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Protocol: HFH DEM 002

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

NIVIA-Hemodynamics
NCT06330597 RECRUITING